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What’s already known about this topic? 
 
 Both emollient and topical corticosteroid treatment (TCS) have been a mainstay of eczema 
treatment for >60 years but the actual quantities used by patients under real-world conditions 
are unknown.  
 
What does this study add? 
 
 Real-world use of emollients is four-fold lower than current guidelines. Underuse of emollients 
may be a significant factor in disease exacerbation. 
 
 Use of TCS is significantly higher in male patients. 
 
 Use of TCS is higher in patients who also have asthma. 
 
 Use of TCS is strongly associated with concurrent anti-depressive treatment. 
 
 
Abstract 
BACKGROUND: Despite decades of use,the actual amounts of topical corticosteroids (TCS) 
and emollients used in moderate-to-severe atopic dermatitis (AD) under real-world 
conditions are unknown. Thus, it remains unclear if inadequate use is widespread. 
OBJECTIVE: To quantify the use of TCS and emollients in moderate-to-severe AD. 
METHODS: Double-blinded drug prescribing recorded prospectively at the point of drug 
dispensing within a catchment of approx. 450,000 over a 31-year period in a population-
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based cohort marked by failure of disease control in primary care (n = 844). For each patient, 
prescribing was recorded over 12-month to minimize fluctuations. RESULTS: The resulting 
dataset was near-complete, and essentially free of reporting- and recording bias. Atopic co-
morbidities matched expected frequencies. Median use of TCS was statistically significantly 
higher in juvenile (age < 16) compared to adult patients (49.2 vs. 38.1 gram / month), in 
males vs. females (46.8 vs. 29.7), and in patients receiving concurrent asthma treatment (40.4 
vs. 26.7). TCS use was strongly associated with anti-depressant treatment. Emollient use was 
unexpectedly low at median of 9.6 gram/day (range 1.4 – 30.1). Results replicated in an 
independent validation cohort. CONCLUSIONS: Deficient use of emollients may be a factor 
contributing to AD severity. TCS use does not exceed current guidelines. Accurate 
quantification of topical treatments provides a widely accessible strategy to measure real-
world impact of novel AD treatments. 
 
Introduction 
Topical treatment with emollients and corticosteroids, the latter first manufactured in 
the 1950s, has been for decades a cornerstone of treatment for atopic dermatitis (AD), 
previously designated ‘neurodermatitis’. Precise quantitative data on the actual amount of 
these agents used have been compiled in a few interventional clinical trials (e.g. 
1
, reviewed 
in 
2
) but are lacking from routine clinical practice beyond estimates in small samples 
3
, 
posing a notable knowledge gap 
4
. As a consequence, it is uncertain how many patients 
(juvenile and / or adult) undergo disease flares or shifts in severity patterns due to inadequate 
topical treatment. Furthermore, it is unclear whether topical treatment significantly differs 
among different age ranges and between genders. The ability to measure “consumption” of 
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topical treatment would also provide a useful outcome measure to assess the impact of 
emerging new drug-based AD treatments, e.g. IL4/IL13 , IL13, or JAK1 
5-7
.  
 We here employed electronic data capture to address this knowledge gap. In a 
population catchment of 450,000, essentially all medical treatment is dispensed by a single 
provider (NHS Tayside), with private providers accounting for less than 5 percent of 
treatment 
8, 9
. All drug prescribing is prospectively electronically captured, as are specialist-
led diagnostic verification and concurrent other dermatological diagnoses. These resources 
allow both quantitative analysis of topical treatments, as well as proxy-assignment of medical 
diagnoses based on drug prescribing. 
 Using this data resource, we here report a detailed quantitative analysis of both topical 
corticosteroid and emollient used in moderate-to-severe AD. Our data reveal a number of 
unexpected associations between drug usage, comorbidities, and other factors. Importantly, 
our data suggest that “the quantitative measurement of topical treatments in AD through 
retrieval of health data records is accessible for many health care providers and could provide 
a readily available measure of efficacy for newly introduced drug treatments.” 
Materials and Methods 
Ethics statement: All data generated in this study were obtained in accordance with 
the Declaration of Helsinki and in compliance with local governance approval regulations 
(Approval by: NHS Tayside Caldicott guardian committee, approval number 
IGTCAL4187++; Photonet, IGTCAL3519; R&D, 2017DS08). In accordance with local 
governance regulation, patient identifiable information was anonymized by the Health 
Informatics Centre Tayside (HIC; www.farrinstitute.org).  
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STROBE statement: This is an observational cohort study. In accordance with the 
STROBE checklist 
10
, background and objectives are specified in the Introduction. Design, 
setting, participants, variables, data sources, quantitative variables, statistical methods used, 
and bias (reporting as well as selection) are discussed below and in Results. All other 
elements listed in the STROBE checklist, specifically Limitations, are listed in Results and 
Discussion.  
Study design: This study employs combined prospective / retrospective design 
elements as follows: Study endpoints, including all parameters of drug usage, IgE results 
were collected prospectively and double-blinded (see below). Study design, analysis, and 
data interpretation were performed retrospectively. Details on observational window and 
patient cohort assembly are given below. 
Observational window: The observational window for this study was defined between 
1 January 1986 to 1 September 2017. This observational window was chosen as maximal 
period yielding complete coverage of prescribing information, laboratory data, and 
demography-linked data.  
Patient selection strategy: The aim of the study was to quantify drug usage in patients 
with AD of moderate-to-severe extent with disease affecting not only selected body sites. 
Mild-to-moderate AD is managed within primary care in Scotland. Once referred to 
secondary care, the triage/treatment pathway operative in NHS Tayside is as follows: if the 
condition is manageable with topical treatments, issue advice and discharge back to GP. If 
not, consider phototherapy (specifically NB-UVB). If not suitable (for any reason), consider 
addition of systemic drugs to topical treatments. Therefore, in order to identify AD patients 
not controlled by topical treatments, patients were initially screened using the Photosys 
database (www.photonet.scot.nhs.uk). This screen was simultaneously used to exclude 
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patients clinically assessed to require treatment only to localised sites (e.g. scalp, hands only). 
The resultant initial dataset of n = 859 patients were largely naïve to third line treatments (see 
Results, Table 1). 
Cohort refinement and validation: The Photosys-derived dataset was linked with a 
dermatology-curated database (Dermabase). This linkage allowed for verification of AD 
diagnosis as well as identification and elimination of concurrent dermatological diagnoses as 
confounders. Fifteen patients had other diagnoses at the time of referral (e.g. psoriasis, 
urticaria, acne), leaving a total of n = 844. 5.6 % of patients within this final cohort had 
recorded other concomitant skin conditions. Data were analysed with and without this subset 
to exclude confounding effects (Table S1).  
Prescribing information, clinical profiling and data refinement: The cohort delineated 
above was linked to the Scotland-wide drug prescribing database. This identified 424,584 
prescription incidents. These were linked with prescription items and matched with the 
clinical patient cohort (n= 844), yielding a total of 351,673 prescriptions. Prescriptions filled 
outside of the observational window (12 months before initiation of phototherapy) were 
removed, leaving a final of n= 29,929 verified prescription incidents. 
Quantification of drug prescribing: All drug quantities analysed were recorded at the 
time of dispensing. AD-relevant medications prescribed to the clinical patient cohort were 
recorded by section code in the British National Formulary (BNF). This, a list of emollient 
and TCS items, along with an analysis of compliance and quantity distribution analysis, is 
detailed in the Supplement.  
Quantification of IgE: The IgE status of the patient cohort was obtained from HIC. 
IgE levels were measured in kU/l with local reference values for normal range in adults being 
5 -120 kU/l. IgE data were available for n = 301 patients. IgE entries had accumulated for this 
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sub-cohort independently of referral to dermatology and consequently had been recorded 
unrelated to the observational window used for drug prescribing. Therefore, for the purpose 
of the present study, IgE values were employed as a proxy for “maximal observed IgE 
potential” for a given individual and not in relation to AD severity. Consequently, whenever 
multiple IgE entries were available for an individual patient, the highest IgE value (rather 
than average) was recorded. 
Assembly of control population cohort: Data on the control population cohort (Table 
1) was retrieved from National Records of Scotland (NRS) and the Information Service 
Division (ISD) Scotland as detailed in the Supplement.  
Calculation of body surface area (BSA) versus frequency of TCS application (see 
Figure 1c) in relation to current guidelines: The principle quantity known from the primary 
data extracted from health records was the monthly amount of TCS dispensed per patient. 
Since the median amount of TCS applied is about 20% higher in male patients (
11
), we 
adjusted the gender – specific amount of TCS required for a single 100% BSA coverage 
accordingly (20 g in males vs. 16 in females) in line with commonly used amounts 
12
. We 
then calculated the frequencies of applications which each patient’s observed TCS use would 
correspond to, assuming a range of affected BSA percentages, using the formula: 
                              
                
                    
                     
In order to account for the observed large inter-individual differences we performed 
this not only with the median observed TCS amount but also with the 25
th
 and 75
th
 
percentiles, respectively, of the TCS quantities used in this cohort to encompass the overall 
range of observed TCS amounts. The resultant graph (Fig.1c) shows the number of 
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applications per month consistent with our data over a wide range of potentially BSA-
percentage that TCS was applied to. 
 Current guidelines [NICE TA81] (https://www.nice.org.uk/guidance/ta81/chapter/1-
Guidance) state that “topical corticosteroids for atopic eczema should be prescribed for 
application only once or twice daily.“ Current SIGN guidelines state “Patients with atopic 
eczema should be advised to apply topical corticosteroids once daily.” 
(https://www.sign.ac.uk/assets/sign125.pdf) 
Statistical Methods. Data analysis and statistical tests were carried out using Stata 
14.0 package (Stata Corp 2015, College Station, TX). Specific tests applied for detection of 
significance are indicated in each respective table and figure legend. 
 
Results 
 Clinical profile of AD patients not controlled in primary care. The most important 
factor impacting on AD treatment is actual disease severity. This is not routinely recorded by 
quantitative scales in clinical practice. In order to capture “more-than-mild” AD severity we 
therefore here used a selection strategy using the criteria: (i) patients seen repeatedly  by their 
GP’s and referred to secondary care, (ii) triaged by consultant-led dermatology review as 
unfit for discharge, (iii) assessed as requiring full body (as opposed to “localised site” only) 
phototherapy. While AD naturally fluctuates in severity, patients in this cohort therefore 
exhibited severity requiring specialist assistance at least on three occasions during the 12-
months observational window: first, at GP-review leading to referral; second, at dermatology 
review (which they did not fail to attend); third, at initiation of phototherapy. It is thus a 
conservative assumption that a “moderate” severity was present for at least 12 weeks out of 
52 weeks (four week interval before each clinical contact) which is characterised by 16 - 30 
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% body surface area involvement.
13
 The age distribution in the resulting cohort (Fig. S1a) 
reflects the cumulative referral-activity among all local GPs and exhibits a bi-modal 
distribution with a large peak in the 16 - 25 year range and a broader peak among older 
patients in addition to juvenile patients. We therefore mapped all subsequent age-related 
subgroup analyses (see below) to three age-range subsets represented in this cohort (0 – 15 / 
16 – 25 / 26+), respectively. In terms of social socioeconomic status, the patient cohort did 
not show bias toward either wealthier or deprived areas (Fig. S1b). As expected, this cohort 
exhibits a high prevalence of atopic co-morbidities, as well as anti-histamine use (Table 1). 
Additional data on drug treatment unrelated to atopic disease do not indicate association of 
AD with a range of other medical conditions (Table S2).  
 Unexpectedly low use of emollients. Table 2, Figure 1a and Figure 1d (left) show 
median, box plot, and distribution, respectively, of average daily emollient usage during the 
year preceding referral to secondary care. Emollient usage ranged between 4.6 – 16.8 g / day 
(25
th
 and 75
th
 percentiles; median: 9.6) for adults and 12 – 30 g / day (median: 17.5) for 
juvenile patients, respectively (Fig. 1a) and did not differ significantly between genders. 
Although the observed use varies between patients, the median overall daily use of approx. 
10g (less than 5g in the lowest quarter, see Fig. 1a) implies that many patients hardly use any 
emollients at all for large time periods throughout one year. This is in stark contrast to current 
guidelines recommending dispensing of 85 g /day (600g / week) for adults and 35 g / day 
(250g / week) for children, respectively. 
14
 
 Confirmation of emollient use in an independent replication cohort. Since the data 
summarised above appeared much lower than expected, we initially performed an exhaustive 
data quality analysis which failed to identify any discernable source for data loss during IT-
processing (see Supplement). However, the overall capture rate of drug prescribing by ISD 
Scotland is not 100 %. Specifically, in our cohort we noted an only 88 % prevalence of 
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emollient use and 90 % prevalence of TCS use (Table 1). We therefore assembled an entirely 
independent replication cohort, consisting of all patients referred to secondary care after the 
original cut-off date (1 Sept 2017, n = 138). Indeed, prevalence of both emollients and TCS 
in this cohort exceeded 97 %, confirming a near-complete rate of data capture by ISD 
Scotland (File: Replication Cohort). Accordingly, there was a slight increase of overall daily 
emollient use (median 12.8 vs. 9.6), as well as TCS use (see below). This entirely 
independent dataset, however, did not yield substantially different outcomes. We conclude 
that, at least in north-east Scotland, real-world use of emollients is almost four-fold lower 
than current guidelines. 
 Median use of TCS in moderate-to-severe AD does not exceed guidelines. The box 
plot and median use of TCS are shown in Fig. 1b and Table 2, respectively. Distribution of 
use is shown in Fig.1d (right). A correlation analysis between emollient and TCS use is 
shown in Fig. S2). Monthly amounts range between 25 – 70 g (25
th
 and 75
th
 percentiles, 
respectively; median: 47) in males and 16 – 53 (median: 30) in females. In terms of potency 
class, as expected, children received lower potent TCS more commonly than adults (Table 
S4). These data did not change appreciably after exclusion of patients with concurrent other 
dermatological diagnoses (psoriasis, urticaria, discoid eczema), confirming that AD was the 
principle driver for the observed TCS use (see Table S1). Furthermore, knowledge of TCS 
quantities allows an estimation of the frequency of application (see Methods). Thus, 
assuming a median of 20 g required for a male and 16 g for a female full body application, 
respectively, and accounting for known inter-individual variabilities 
11, 12
, the TCS use 
observed in this cohort is consistent with anywhere between 5 – 60 TCS applications per 
month across a wide range of possible body surface area sizes (Fig. 1c). This level of use 
does not exceed current guidelines (see Methods). Clearly, inter-individual differences are 
large. However, across the cohort excessive TCS use does not appear to be highly prevalent. 
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Higher TCS use in male patients. Unexpectedly, as detailed above, we observed a 
highly statistically significant gender imbalance among adult patients. The higher TCS use in 
male patients exceeds what could be attributable to the 20 % difference in body surface area 
(BSA) divergence (see Methods) 
11
. There is no apparent explanation accounting for this 
observation.  
High prevalence of antibiotic and oral systemic treatment. We next analysed general 
drug use by AD patients compared to population controls. As shown in Table S2, AD patients 
exhibited age-adjusted treatment profiles identical to background population treatments for a 
wide range of conditions. The two notable exceptions were the prevalence of antibiotic use 
(28.8 % vs. 5.7 %) and oral systemic corticosteroid use (4.4 % vs. 0.7%). This was partly 
owed to the concurrent high prevalence of asthma (Table S3), although even in the asthma-
negative patient subgroup both oral systemic corticosteroid and antibiotic treatment was more 
common than in the control population (Table S3, antibiotic prevalence: 20.0%, oral systemic 
steroids: 2.3 %). 
Increased use of topical corticosteroids in patients requiring asthma treatment. 
Although asthma is associated with AD, reliable data on the effect of asthma on the severity 
of AD are lacking 
15
. The availability of accurate quantitative treatment data allowed us to 
explore the effect of asthma. As expected, use of systemic oral corticosteroids, 
antihistamines, antibiotics, as well as antidepressants 
16
 was higher in AD patients requiring 
treatment for asthma (Table S3). Unexpectedly, however, we also observed a small but 
statistically significant increase in the number of patients using topical corticosteroids in this 
subgroup in all age ranges but especially in older adults (Table 3). The amount of topical 
corticosteroids used per patient was also increased, especially in the juvenile and in the >25 
age groups, respectively (Fig. 2a). This was observed in both genders but was even more 
pronounced in female patients (Fig. S3). In fact, we observed a clear linear correlation 
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between the amount of asthma-inhalers used and the use of corticosteroid (Fig. 2b). The 
apparent effect of Asthma-inhaler usage on topical corticosteroid treatment was independent 
of IgE level, but concurrent IgE elevation and active asthma had an even greater effect (Fig. 
S4). We conclude that, at least in this population, concurrent therapy-requiring asthma 
impacts on the quantity of topical corticosteroids applied by AD patients. 
Topical corticosteroid use is associated with high prevalence of antidepressant 
treatment, independently of asthma status. Sub-group analysis based on asthma status had 
shown an association between antidepressant treatment and asthma (Table S3) as well as 
between asthma and the use of topical corticosteroids (see above). We therefore asked if the 
former association was in fact explained by the use of topical corticosteroids. For this 
purpose, we grouped the use of topical corticosteroids in low vs high, choosing a cut-off 50 g 
/ month based on the distribution of topical corticosteroid use in our population (Fig. 1d 
right). We limited analysis to adult patients since anti-depressant use was virtually absent in 
juveniles (Fig. S5). As shown in Table 4, the prevalence of regular anti-depressant treatment 
was almost doubled in patients applying high amounts of topical corticosteroids (12% vs. 
6%) and this difference was retained in non-asthma patients.  
 
Discussion 
Topical corticosteroids and emollients have been the mainstay of AD treatment. 
Despite extensive study of mechanisms and efficacy in interventional trials, virtually no data 
exist on the actual amount of these compounds applied by patients under real-world 
conditions. The present report is a first step towards addressing this gap. Using a population-
based database-mining approach, we here establish that, at least in Scotland, use of 
emollients dramatically differs from guideline recommendations. Half of AD patients use less 
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than 10 g per day, even after multiple GP consultations and referral to secondary care. Given 
that we extracted twelve-month-average use, the data imply that many patients evidently do 
not use emollients on a daily basis but only as/when they experience flares. Clearly, emollient 
use as a prophylactic to prevent exacerbation is not widespread, in direct contradiction to 
current guideline recommendations. Although the data presented here may differ from other 
populations, the data were replicated almost identically in an entirely independent cohort, 
ruling out deficient data capture. Likewise, it is unlikely to assume that a substantial fraction 
of patients would choose to buy over-the-counter emollients instead of utilising freely 
available compounds. 
The TCS use observed here, between 20-65 gram / month, corresponds to roughly 
0.75 – 2 applications per day across the whole year, which does not exceed guidelines. As 
shown in Figure 1c, an average once-daily application of the median observed TCS amount 
would equate to approximately 7.5% body surface area. Given that moderate AD equates to 
BSA involvement between 15-40%, it is therefore likely that patients, at least at the time of 
referral, dermatology review, and initiation of phototherapy, respectively, would exhibit 
higher BSA involvement. Even accounting for intervening periods of remission (which our 
data cannot capture), the observed level of TCS use would appear overall on the low end of 
the expected. In terms of underlying factors, the observed significantly higher use of TCS in 
juvenile patients (where parents may often be involved in treatment) suggests that “steroid 
phobia” (
17, 18
) is unlikely to be a major factor underlying moderate TCS use.  
One of the difficulties in obtaining high quality real-world data is the definition of 
cohorts with relatively homogenous severity ranges. In this regard, we here employed an 
approach targeting a defined observational window prior to specialist-care referral, as well as 
specialist-based triage toward a full-body treatment approach. Our data clearly suggest that a 
moderate-to-severe cohort profile can be extracted from population based data in the absence 
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of dedicated scores, which are not routinely available. Prescribing data analogous to those 
held by NHS Scotland are available for many other health care providers, suggesting that the 
methodology presented here can be adapted widely. 
We unexpectedly observed that patients requiring ongoing asthma-treatment use 
significantly higher amounts of topical corticosteroids (Fig.3). Although much has been 
written about concurrent atopy, including asthma, and the so-called ‘atopic march’, we were 
unable to identify any published reports on an effect of atopic co-morbidities on skin-targeted 
steroid treatment. The magnitude of the effect as well as independence of confounding 
additional atopic manifestations strongly argues against an artefact. Possibly, patients who 
are used to taking treatments for asthma could be more adherent to their topical 
treatments.  Alternatively, or in addition, TCS, although prescribed and consciously applied 
to affect AD, might also contribute to asthma control via percutaneous absorption. A third 
possibility is that patients with coexisting asthma and AD have more severe disease.  
We find that the prevalence of patients requiring repeat antidepressant prescriptions is 
twice as high in AD patients using high vs. low amounts of topical corticosteroids (12% vs. 
6%, table 4). These data confirm previously reported associations between AD and 
depression in adults 
19
 and children 
20
 and further validate the use of quantitative drug 
prescribing data to obtain clinically relevant ‘holistic’ treatment read-outs. In this regard, 
perhaps the most obvious application of the approach presented herein will be the 
confirmation and quantification of benefit for AD patients of novel, and often resource-
intensive treatments, e.g. dupilumab. Use of database-based real-world studies circumvents 
the need for dedicated feedback-elicitation, thereby reducing bias.  
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Finally, our data exhibit a number of obvious limitations. First, use of drug treatment 
as proxy for medical diagnoses may not capture clinically confirmed diagnoses in non-atopic 
conditions. Second, our data were obtained in a genetically rather homogenous population 
21
 
and may be of limited predictive value for other populations. Third, there is a degree of 
uncertainty on the actual use of topical drugs, as quantities analysed here are recorded at drug 
dispensing (for details, see Methods). Forth, sub-analyses reported age-group specific 
findings by necessity exhibit limited numbers of observations.  
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Table 1. Clinical characteristics of the Tayside atopic dermatitis cohort1 
 AD patients (n = 844) 
Age (median ± s.d.) 25 ± 16.5 
8.2 % Juvenile (age ≤ 15) 
Gender (% female) 53.1 % 
Asthma2 243 (28.8%) 
Elevated total IgE (%)3 
Allergic rhinitis (%) 
249 (82.5%) 
93 (11.0%) 
Anti-histamine use (%) 582 (69.0%) 
Emollient use (F / M) (%) 745 (88.3%) 
Topical corticosteroid use (F / M) (%) 762 (90.3%) 
Oral systemic corticosteroid treatment 167 (19.8 %) 
Other systemic treatment for AD4 6 (0.7 %) 
 
1 Clinical characteristics for patients not adequately controlled in primary care with 
minimum duration of 12 months AD (see Methods).  
2 Defined by regular use of BNF-coded preparations (see Methods).  
3 Defined as total IgE > 120 kU / l. 
4 Comprises methotrexate, cyclosporine, azathioprine. 
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Table 2. The amount of emollients and topical corticosteroids used by AD patients 
during a twelve month period before referral to secondary care.1 
 
 Usage by age - range 
 0 – 15  16 – 25 > 25 
TCS (g/month) 49.2 ± 50.4 35.0 ± 38.4**2 38.1 ± 49.8*2 
Emollients (g/day) 17.5 ± 30.8 9.9 ± 13.3***2 9.6 ± 18.3***2 
Emoll / TCS3 7.5 ± 1.4 6.5 ± 3.0 6.2 ± 3.6 
 Usage by gender and age - range 
 TCS (gram / month) 
   0 – 15     16 – 25      > 25 
Female 48.9 ± 54.5 32.5 ± 32.3*3 26.6 ± 32.7***4 
Male 49.2 ± 47.1 37.5 ± 44.4 52.1 ± 58.2 
 Emollients (gram / day) 
Female 15.2 ± 18.9   9.6 ± 11.7   7.9 ± 19.0*4 
Male 18.4 ± 38.3 10.3 ± 14.9 10.1 ± 17.6 
Emoll/TCS female3 7.5 ± 1.4   6.5 ± 2.4   6.5 ± 4.1 
Emoll/TCS male3 7.5 ± 1.5   6.5 ± 3.7   5.7 ± 3.1 
 
1 Data shown represent median ± s.d., respectively, for all patient that have been 
treated with TCS (n = 762) and emollient (n = 745), respectively, as indicated in the 
table since data were non-Gaussian distributed (see Fig 1d). TCS subgroup sample 
sizes were for females: 0-15: n = 28, 16-25: n = 180, >25: n = 189; for males: 0-15: n 
= 31, 16-25: n = 148, >25: n = 186. Emollient subgroup sample sizes were for 
females: 0-15: n= 27, 16-25: n = 179, >25: n= 183; for males: 0-15: n = 31, 16-25: n 
= 144, >25: n = 181. 
2 between age-range significance (vs. age-range “0 – 15”): * p < 0.05; ** p < 0.01, *** 
p < 0.001 (Kruskal Wallis rank test). 
3 ratios calculated for each patient, then by age groups.  
4 between-gender significance: * p < 0.05; ** p < 0.01, *** p < 0.001 (Wilcoxon rank-
sum test). 
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Table 3. The association of topical corticosteroid use in AD patients with asthma 
status.1 
Age-range (y) Prevalence of topical corticosteroid treatment 
 Regular asthma – treatment2 
 no yes 
   n  % [95 % C.I.] n % [95 % C.I.] 
 0 - 15  36 78 [66 – 91]  23 100 [ -- ] * 
16 - 25 243 89 [85 – 93]  85 96 [92 – 100] * 
 > 25 246 87 [83 – 90] 129 97 [95 – 100]** 
 
1 Percentage of AD patients receiving prescriptions for topical corticosteroids within 
12 months before referral to secondary care. 
2 Defined as minimum of three prescribed asthma inhalers per twelve months (see 
Methods). 
* p < 0.05, ** p < 0.001 (Pearson’s chi-squared test). 
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Table 4. The association between use of topical corticosteroids and anti-depressant 
treatment.1 
 
 Prevalence of patients using regular antidepressants 
 Topical corticosteroid usage: 
 Low2 High2 
 % [95% C.I.] n % [95% C.I.] n 
All patients 7.6 [5.4 – 9.9] 524 12.5 [8.2 – 16.8]* 232 
Asthma: no 6.0 [3.6 – 8.3] 400 12.6 [7.0 – 18.1]* 143 
Asthma: yes 12.9 [5.4 – 19.3] 124 12.4 [6.9 – 18.8 ]   89 
 
1 At least three repeat anti-depressant prescriptions in twelve months. Figures set in 
bold print met statistical significance. * p = 0.01 (Pearson’s chi-squared test) 
2 Low: ≤ 50 g / month; High: ≥ 50 g / month  (see Fig. 1d right for selection of cut-off).  
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Legends to Figures 
 
Figure 1. The use of topical agents in moderate-severe AD. (a) Daily usage of 
emollients by gender (left), and broken down by age/gender (right). Boxplots show 
the median (horizontal bar), 25th and 75th percentile (boxes), as well as range 
(min/max), respectively, of average monthly usage across one year. (b) Same as in 
(a) for monthly use of topical corticosteroids. Horizontal lines indicate 50th percentile 
(** p < 0.001). (c) Projected number of applications per month of topical 
corticosteroid use for male (left) and female (right) patients based on the observed 
median (dashed line), as well 25th and 75th percentile use (grey shaded), across the 
range of possible body-surface-areas involvement. The boxed regions demarcate 
BSA percentages exposed to TCS at once to twice daily applications. The data show 
that less than median 5% BSA involvement across the cohort would correlate with 
more than twice-daily TCS application and is therefore highly unlikely. (d) Distribution 
of daily emollient use, shown in log format (gram / day, left, one bar represents 2g), 
as well as TCS, shown in linear format (gram / month, right, one bar represents 10g) 
broken down by gender. The horizontal lines on top in the TCS graph denote 
grouping into “low” vs. “high” groups of corticosteroid usage. 
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Figure 2. The association of topical corticosteroid use in AD with asthma. (a) Monthly 
corticosteroid usage broken down by age group and asthma requiring active 
treatment (“yes” = three or more inhaler prescriptions per year). * p < 0.05, ** p < 
0.01 (t-test). (b) Correlation between the number of Asthma-prescriptions and 
monthly use of topical corticosteroid use. Asthma-treatment groups selected to 
generate even groups sizes between asthma-subgroups and were as follows: “0” = 
no inhalers (n = 520, “1” = 1 – 2 inhalers (average 1.7, n = 102), “2” = 3-7 inhalers 
(average: 5.6, n = 105), “3” ≥ 9 inhalers (average 16.6, n = 117). 
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